Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Jack

Showing results (361-370 of 594) with videos related to

Pageof 60
Sort By:
Cancer|February 24, 2012
Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitorsWoo-Young Kim, Ludmila Prudkin, Lei Feng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2024
Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell CarcinomasFaye M Johnson, Madison P O'Hara, Lacin Yapindi, et al.
Cancer Research|October 16, 2012
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trialsFilip Janku, Jennifer J Wheler, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2011
Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosisXiming Tang, Humam Kadara, Carmen Behrens, et al.
Molecular Cancer Research : MCR|December 1, 2016
High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIVHeather M Walline, Thomas E Carey, Christine M Goudsmit, et al.
Journal of the National Cancer Institute|April 5, 2017
A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic CancerSeetharaman Balasenthil, Ying Huang, Suyu Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancerGustavo Schvartsman, S Andrew Peng, Giorgios Bis, et al.
Neurobiology of Pain (Cambridge, Mass.)|May 22, 2026
Sex differences in nerve injury-induced neuropathic pain via REST in primary sensory neuronsAadhya Tiwari, Ashok Subedi, Asieh Etemad, et al.
The Oncologist|August 30, 2014
A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancerKathryn A Gold, J Jack Lee, Nusrat Harun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinomaAbenaa M Brewster, J Jack Lee, Gary L Clayman, et al.
Pageof 60

Showing results (361-370 of 594) with videos related to

Sort By:
Pageof 60
Cancer|February 24, 2012
Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitorsWoo-Young Kim, Ludmila Prudkin, Lei Feng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2024
Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell CarcinomasFaye M Johnson, Madison P O'Hara, Lacin Yapindi, et al.
Cancer Research|October 16, 2012
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trialsFilip Janku, Jennifer J Wheler, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 25, 2011
Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosisXiming Tang, Humam Kadara, Carmen Behrens, et al.
Molecular Cancer Research : MCR|December 1, 2016
High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIVHeather M Walline, Thomas E Carey, Christine M Goudsmit, et al.
Journal of the National Cancer Institute|April 5, 2017
A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic CancerSeetharaman Balasenthil, Ying Huang, Suyu Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancerGustavo Schvartsman, S Andrew Peng, Giorgios Bis, et al.
Neurobiology of Pain (Cambridge, Mass.)|May 22, 2026
Sex differences in nerve injury-induced neuropathic pain via REST in primary sensory neuronsAadhya Tiwari, Ashok Subedi, Asieh Etemad, et al.
The Oncologist|August 30, 2014
A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancerKathryn A Gold, J Jack Lee, Nusrat Harun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2007
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinomaAbenaa M Brewster, J Jack Lee, Gary L Clayman, et al.
Pageof 60